The first 6 months of 2026 brought a wave of meaningful developments in women's health, and our readers made clear which stories resonated most. The following 10 articles represent the most-viewed content on Contemporary OB/GYN from January through June 2026, a list driven entirely by our audience, reflecting what clinicians are reading, sharing, and returning to most.

Contemporary OB/GYN’s top articles for 1H 2026

FDA says “study may proceed” for Vistagen’s refisolone nasal spray for vasomotor symptoms

Published April 22, 2026, this article reported that Vistagen received a “Study May Proceed” letter from the FDA, clearing the path for continued phase 2 development of refisolone, a non-hormonal, non-systemic intranasal candidate for moderate-to-severe menopausal vasomotor symptoms.¹ In an earlier exploratory phase 2a trial, refisolone reduced hot flash frequency by 80% compared to 36% for placebo, with improvements observed as early as 1 week and no serious drug-related adverse events reported.¹

Click here for full details.

Shifting treatment expectations in the evolving landscape of female pelvic health

Clinicians discussed how evolving treatment options are reshaping expectations in female pelvic health, covering the spectrum of therapeutic approaches available to patients with pelvic floor disorders.² Practical clinical perspectives on how providers can guide patients through an increasingly diverse menu of both surgical and non-surgical options.²

Click here for full details.

FDA approves 5-year use for etonogestrel implant 68 mg contraceptive

Published January 19, 2026, this article covered the FDA’s approval of a supplemental NDA extending the duration of use for the etonogestrel implant (Nexplanon; Organon) from 3 years to up to 5 years.³ The decision was supported by a multicenter, single-arm, open-label study (NCT04626596) in which no pregnancies were reported during years 4 and 5 of use, with a Pearl Index of 0.0 pregnancies per 100 women-years (95% CI: 0.00–0.69) and no new safety findings identified.³

Click here for full details.

EP 1: Management of hypothyroidism during menopause clinical cases

In this video series, we highlighted the clinical challenge of managing hypothyroidism in menopausal women, opening with a case focused on the role of dietary supplements.⁴

Click here for full details.

Global consensus renames PCOS to polyendocrine metabolic ovarian syndrome (PMOS)

Published May 12, 2026, this article covered a landmark health policy published in The Lancet, in which a global consensus process involving 56 academic, clinical, and patient organizations — and more than 14,300 survey respondents — formally renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS).⁵ The new name was adopted to address longstanding concerns that “PCOS” was a misnomer, misleadingly implying pathological ovarian cysts while obscuring the condition’s broader endocrine and metabolic features.⁵

Click here for full details.

FDA clears ENDO-205 investigational new drug application for endometriosis

On March 23, 2026, the FDA cleared an Investigational New Drug application for ENDO-205 (EndoCyclic Therapeutics), a first-in-class, non-hormonal targeted peptide therapeutic in development for endometriosis — a disease affecting more than 190 million girls and women worldwide — with a phase 1 clinical study among premenopausal women planned to follow.⁶ According to the company, ENDO-205 is the first therapy in development designed to eliminate endometriosis lesions and address associated symptoms, including pain and systemic complications.⁶

Click here for full details.

Romosozumab increased bone density in postmenopausal women regardless of age

Published February 25, 2026, this article covered a prospective observational study published in Bone finding that older age did not diminish bone mineral density (BMD) response to romosozumab in postmenopausal women, with a mean BMD increase of 9.16% at the lumbar spine and 3.00% at the total hip after 12 months of therapy.⁷

Instead, lower baseline BMD, particularly at the total hip, was the factor independently associated with greater treatment response, supporting the use of romosozumab across a broad age range in routine clinical practice.⁷

Click here for full details.

Wearable device designed for perimenopause launches

This April 2, 2026, news item reported on the commercial launch of a wearable device specifically designed for perimenopausal women, entering a growing digital health market focused on the menopause transition. Data collected by the device contributed to the 1st large-scale perimenopause dataset, aimed at improving clinical decision-making and long-term health outcomes.⁸

Click here for full details.

FDA updates labels on multiple menopausal hormone therapies

Published February 12, 2026, this article reported on the FDA’s approval of label changes for 6 menopausal hormone therapy products, including the removal of certain risk statements related to cardiovascular disease, breast cancer, and probable dementia from the products’ boxed warnings.⁹ The updated labeling spanned 4 categories of HRT: progestogen alone, systemic estrogen alone, topical vaginal estrogen, and combination systemic estrogen and progestogen, covering products including Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva.⁹

Click here for full details.

NIRVANA: Elinzanetant cuts objective wakefulness in menopausal women

Published June 17, 2026, this article covered findings from the exploratory phase 2 NIRVANA trial (NCT06112756) presented at SLEEP 2026 in Baltimore, which found that elinzanetant (Lynkuet) produced a numerically greater reduction in PSG-measured wakefulness after sleep onset (WASO) compared with placebo in postmenopausal women with vasomotor symptoms and objectively confirmed sleep disturbance.¹⁰

The effect was most pronounced at week 4, with a 28% greater reduction in WASO with elinzanetant versus placebo at that timepoint, and an overall 18% greater reduction across the full 12-week treatment period in a post hoc model accounting for night-to-night variability.¹⁰

Click here for full details.

Don’t miss any updates from Contemporary OB/GYN

Thank you for filling out your details and reading with us! To keep in touch with the latest news for today’s ob-gyn, consider subscribing to our free biweekly e-newsletter, which features our latest headlines, conference coverages, and expert video interviews.

Click here to sign up.

References:

1. FDA says “study may proceed” for Vistagen’s refisolone nasal spray for vasomotor symptoms. Contemporary OB/GYN. Published April 22, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/fda-says-study-may-proceed-for-vistagen-s-refisolone-nasal-spray-for-vasomotor-symptoms
2. Shifting treatment expectations in the evolving landscape of female pelvic health. Contemporary OB/GYN. Published April 2, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/shifting-treatment-expectations-in-the-evolving-landscape-of-female-pelvic-health
3. FDA approves 5-year use for etonogestrel implant 68 mg contraceptive. Contemporary OB/GYN. Published January 19, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/fda-approves-5-year-use-for-etonogestrel-implant-68-mg-contraceptive
4. EP 1: Management of hypothyroidism during menopause clinical cases. Contemporary OB/GYN. Published March 23, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/ep-1-management-of-hypothyroidism-during-menopause-clinical-cases
5. Global consensus renames PCOS to polyendocrine metabolic ovarian syndrome (PMOS). Contemporary OB/GYN. Published May 12, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/global-consensus-renames-pcos-to-polyendocrine-metabolic-ovarian-syndrome-pmos-
6. FDA clears ENDO-205 investigational new drug application for endometriosis. Contemporary OB/GYN. Published March 23, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/fda-clears-endo-205-investigational-new-drug-application-for-endometriosis
7. Romosozumab increased bone density in postmenopausal women regardless of age. Contemporary OB/GYN. Published February 25, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/romosozumab-increased-bone-density-in-postmenopausal-women-regardless-of-age
8. Wearable device designed for perimenopause launches. Contemporary OB/GYN. Published April 2, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/wearable-device-designed-for-perimenopause-launches
9. FDA updates labels on multiple menopausal hormone therapies. Contemporary OB/GYN. Published February 12, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/fda-updates-labels-on-multiple-menopausal-hormone-therapies
10. NIRVANA: Elinzanetant cuts objective wakefulness in menopausal women. Contemporary OB/GYN. Published June 17, 2026. Accessed July 1, 2026. https://www.contemporaryobgyn.net/view/nirvana-elinzanetant-cuts-objective-wakefulness-in-menopausal-women